Skip to main
LNTH

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings Inc is positioned for significant growth, particularly with its POSLUMA product, which is expected to achieve high single-digit market share in PSMA PET imaging revenue, a notable increase from prior quarters. Additionally, the introduction of a new Pylarify formulary, which boosts batch sizes by approximately 50% and extends TPT eligibility for three years, is anticipated to revitalize growth for the product starting in the fourth quarter of 2026. Finally, the potential for enhanced contribution margins from non-Pylarify segments may lead to surpassing current EPS expectations for 2026-2027, further bolstering the company's financial outlook.

Bears say

Lantheus Holdings Inc. has reported a decline in Pylarify revenue, which amounted to $260 million, reflecting an 8% year-over-year decrease and falling short by approximately $14 million of market expectations. Additionally, the company experienced lower-than-expected growth in unit sales, achieving only a 2% increase year-over-year and facing a 10% price headwind during the quarter. Compounding these challenges, Lantheus Holdings' growth profile is now projected to lag behind that of profitable small to mid-cap MedTech peers for 2025-2026, suggesting an overall weak financial outlook.

Lantheus Holdings (LNTH) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 6 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Dec 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.